Medical/Pharmaceuticals
Anthill Cloud: Transforming Pharma Marketing with AI, Modular Content, and Omnichannel Engagement
COPENHAGEN, Denmark, Nov. 3, 2025 /PRNewswire/ -- Anthill
2025-11-03 17:00
1195
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management
* Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health c...
2025-11-03 16:48
1285
Sandstone Easydrip™ Plus with Hextra Tech™ Hexagonal Broad Hub Delivers Steadier, More Comfortable Insulin Injections
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- A peer-reviewed article by researchers at the University ofShanghai for Science and Technology (USST), published in an international biomedical engineering journal, reports that the Hextra Tech™ hexagonal, broad-platform hub used in Sandstone Easydrip™ Plus ...
2025-11-03 14:35
997
Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes. YOKOHAMA, Japan, Nov. 3, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment1, today announced th...
2025-11-03 14:35
1240
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRA...
2025-11-03 13:26
1101
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Desi...
2025-11-03 12:12
1197
OMANI PATIENTS GAIN DIRECT ACCESS TO MALAYSIAN MEDICAL SPECIALISTS THROUGH WEEK-LONG HEALTHCARE ACTIVATION
SEEB, Oman, Nov. 3, 2025 /PRNewswire/ -- Malaysia Healthcare Week opens at City Centre Mall, Seeb, marking the first majorMiddle East activation under the Malaysia Year of Medical Tourism (MYMT) 2026. The week-long programme connects Omani patients with Malaysian medical specialists through publi...
2025-11-03 11:19
1367
Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the ...
2025-10-31 21:00
2173
Bio Farma Indonesia Leads Global Vaccine Manufacturers as Host of the 26th DCVMN AGM in Bali
BALI, Indonesia, Oct. 31, 2025 /PRNewswire/ -- Bali, October 29, 2025, Indonesia , throughBio Farma, is hosting the 26th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers Network (DCVMN) inBali on October 29–31, 2025. The forum brings together vaccine manufacturers, ...
2025-10-31 20:01
2555
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku,Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the in...
2025-10-31 20:00
1627
Elevaris Medical Devices Names New Chief Engineering and Operations Officer
BOSTON, Oct. 31, 2025 /PRNewswire/ -- Elevaris Medical Devices, a Contract
Development and Manufacturing Organization for industry-leading multi-national
healthcare companies, announced the appointment of its new Chief Engineering
and Operations Officer,Salvador Montes.
2025-10-31 20:00
1289
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
FRANKFURT, Germany, Oct. 31, 2025 /PRNewswire/ -- From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international commercialization solutions to partners from glo...
2025-10-31 19:50
1754
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with R...
2025-10-31 17:38
1430
Xinhua Silk Road: Chinese biz leaders hold talks to explore cultural inheritance, innovation
BEIJING, Oct. 31, 2025 /PRNewswire/ -- On Tuesday, an in-depth talk between board chairmen of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) and Kweichow Moutai Group highlighted joint effort to promote inheritance and innovation of traditional Chinese culture. After discussi...
2025-10-31 16:15
952
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by "Championing the Missions that Matter™"
TAMPA, Fla., Oct. 31, 2025 /PRNewswire/ -- Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focu...
2025-10-31 08:30
1169
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
* NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise inGreater China and other Asian markets * Nov...
2025-10-30 16:15
1201
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as ofOctober 29, 2025 * The interchangeability (IC) designations o...
2025-10-30 15:28
1313
United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the compa...
2025-10-30 13:58
958
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 inGreater China, Singapore, South Korea, and certain Southeast Asian countries. * Under the assigned exclusive license, Everest Medicines will make an upfront payment ofUS$7 million (equivalen...
2025-10-30 11:05
1521
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
* Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. * The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported...
2025-10-30 09:15
1683
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 301 media titles]
2026-01-21 12:39JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
